 Shares of BioSpecifics Technologies NASDAQ:BSTC rose 2 in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 87.36 over the past year to 0.11, which beat the estimate of 0.05.Revenue of 3,903,000 decreased by 55.91 from the same period last year, which beat the estimate of 2,060,000.Guidance Earnings guidance hasnt been issued by the company for now.View more earnings on BSTCBioSpecifics Technologies hasnt issued any revenue guidance for the time being.Technicals Companys 52-week high was at 69.51Companys 52-week low was at 42.00Price action over last quarter: Up 19.01Company Overview BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytrens contracture and Peyronies disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.See more from Benzinga Stocks That Hit 52-Week Highs On TuesdayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 